DEVELOPMENTAL MECHANISMS OF HUMAN STRUCTURAL BIRTH DEFECTS
RELEASE DATE: January 28, 2004
PA NUMBER: PA-04-052 (Reissued as PA-07-419)
EXPIRATION DATE: February 15, 2007, unless reissued
Department of Health and Human Services (DHHS)
PARTICIPATING ORGANIZATION:
National Institutes of Health (NIH)
(http://www.nih.gov)
COMPONENT OF PARTICIPATING ORGANIZATION:
National Institute of Child Health and Human Development (NICHD)
(http://www.nichd.nih.gov/)
CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER(S): 93.865
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this PA
o Research Objectives
o Mechanism of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
The purpose of this PA is to support new, innovative, multidisciplinary,
interactive, and synergistic program projects that integrate basic,
translational, and clinical approaches to understanding the developmental
biology and genetic basis of congenital human malformations. Each program
must consist of at least three component projects. At least one project must
be clinical or translational in nature. The component projects must share a
common central theme, focus, or objective on a specific developmental defect
or malformation that is genotypically, mechanistically, biologically, or
phenotypically analogous or homologous in both animal models and humans. Any
non-mammalian or mammalian animal model may be used, as long as it
contributes to the common overall theme or objective of the program project.
If the component projects do not share a common developmental gene, process,
mechanism, pathway, or phenotype, the application will be considered
nonresponsive to this PA.
RESEARCH OBJECTIVES
Background
Annually, about four percent of all live births in the United States involve
babies with significant structural birth defects (more than 150,000 babies).
Next to accidents, birth defects are the leading cause of death in children;
they account for half of all pediatric hospitalizations. In terms of the
economic costs, billions of dollars are spent over the lifetimes of children
born with any of 17 major, severe, nonfatal birth defects. In sum, structural
birth defects have a great impact on public health, socioeconomics, and
family life. A high priority goal of NICHD's strategic plan is to address the
problem of human structural birth defects.
The clinical and epidemiological aspects of human malformations were
addressed at a workshop in 1997. As a result of that workshop, NICHD, NIEHS,
NIDCR, and the EPA issued RFA HD-99-002, "Genetic Susceptibility and
Variability of Human Malformations." That initiative funded several R01s and
established a basis for a network of investigators focused on the use of
molecular genetic approaches to the study of genetic susceptibility and
epidemiology of human malformations.
A second workshop was held in 1998 and its recommendations served as the
basis for RFA HD-99-008, "Developmental Mechanisms of Human Malformations",
from which NICHD and NIEHS funded several P01s. An important feature of those
P01s was the emphasis on integrating basic, translational, and clinical
research. Combined with the R01s funded under the first initiative, these
projects expanded the network of researchers focused on the study of
structural birth defects.
By issuing this PA, "Developmental Mechanisms of Human Structural Birth
Defects," the NICHD plans to increase the number of basic scientists and
clinicians involved in this network. Now that the sequencing of the human
genome is complete, it is time to capitalize on the rapid advances being made
in functional genomics and proteomics. Broadening the base of PIs involved in
this research effort will promote the translation of these advances from the
bench to the bedside.
Scope
The purpose of this PA is to support new, innovative, multidisciplinary,
interactive and synergistic program projects that integrate basic,
translational, and clinical approaches to understand the developmental
biology and genetic basis congenital human malformations.
Of particular interest to the NICHD are applications proposing to study
embryonic developmental defects of generalized body patterning and localized
anomalies of the skeletal, nervous, and visceral systems that lead to
clinically significant congenital structural malformations.
While applications focusing on developmental disorders that result in mental
retardation and related neurobehavioral disabilities are of interest to the
NICHD, they are outside the scope of this PA.
The basic science component projects may include studies to: 1) identify and
characterize the genes, gene products, mutations, polymorphisms, multigene
and gene/environment interactions that play a role in normal and abnormal
embryonic patterning and organogenesis; 2) elucidate the developmental
biological processes and pathways, the biochemical, cellular, molecular,
genetic mechanisms, and spatial and temporal gene expression patterns which
are involved in dysmorphogenesis; and 3) examine how teratogens and
nutritional deficiencies disrupt or modify gene expression and basic
developmental processes.
The translational/clinical component projects may include studies to: 1)
characterize and classify genotypes and phenotypes of human malformations
that are comparable in the animal models being examined; 2) develop physical,
genetic, and comparative maps for genes involved in human malformations; 3)
identify the developmental genetic processes and molecular pathogenesis of
human malformations utilizing animal models; and 4) develop innovative
molecular genetic methods, technologies, and strategies to enhance the
diagnosis and methods for intervention of the human malformations.
Applicants are encouraged to incorporate the recent scientific advances in
developmental biology and genetics in their projects and to utilize the many
research resources, bioinformatic databases, and biotechnological tools in
their research cores. The research cores should be structured to share work
effort and research resources (e.g., biotechnology, high-throughput
instrumentation, microarrays, oligonucleotide chips, animal model
development, and technical assistance) among the research projects. The aim
of the core is to enhance the progress, productivity, cost-effectiveness, and
outcome of the research projects.
Applications may include new and innovative approaches to investigate: 1)
genetic defects, nutritional deficiencies, teratogens that perturb, modify,
or alter gene expression during early development; 2) the identity and
function of transcription and growth factors in normal and abnormal
gastrulation, embryogenesis, organogenesis, and patterning, as well as their
modification by environmental agents; and 3) defective embryonic
developmental processes and pathways that ultimately lead to malformations.
Research projects responsive to this PA include, but are not limited to, the
following:
o Investigations on the identity, characteristics, and mechanisms of growth
factors and growth factor receptors that function in embryonic development
and dysmorphogenesis of the skeletal, nervous, and visceral systems;
o Studies of transcription factors regulating gene expression and temporal
and spatial expression patterns during normal and abnormal embryonic
development;
o Studies of developmental genes, gene products, transcription factors, and
growth factors that function and interact to regulate cell proliferation,
cell differentiation, apoptosis, cell migration, and cell fate in embryonic
development;
o Examination of genes and molecular mechanisms and interactions that control
normal and abnormal body axes and symmetry during development;
o Studies to identify, map, and characterize genes that play a role in:
signal transduction and biochemical pathways, cell fate determination,
gastrulation, embryogenesis, organogenesis, body patterning and how
developmental defects, mutations, or susceptible polymorphisms lead to
malformations;
o Investigations of pharmaceutical, nutritional, and teratogenic agents and
factors that alter genes and developmental processes and pathways that result
in dysmorphologies;
o Investigations to characterize and classify genotype/phenotypes of
hereditary human malformations and correlate them to homologs in animal
models;
o Efforts to define pleiotropic effects that genes and their modifiers have
in the spatial and temporal development of embryonic and/or fetal anomalies;
o Development and validation of new and/or improved animal models to study
the genes, mutations, mechanisms, and developmental processes and pathways
that cause human malformations;
o Imaging and gene expression studies to investigate and monitor the
developmental pathogenesis of dysmorphic features;
o Investigations of the role of imprinting and epigenetic factors in the
development of major congenital malformations;
o Studies on nutritional factors (e.g., folic acid deficiency) and teratogens
(e.g., retinoids and valproic acid) affecting gene/gene, gene/receptor,
gene/modifier, and gene/teratogen interactions that lead to neural tube or
other structural defects;
o Examination of the role and developmental biology of neural crest cells in
normal embryonic development and how defects in cell proliferation,
differentiation, migration, and patterning may result in major structural
birth defects;
o Elucidation of the underlying genetic and molecular mechanisms that alter
normal developmental processes in drug-induced (e.g., Accutane, Thalidomide)
malformations;
o Identification and characterization of polymorphisms/mutations of metabolic
genes that function in the development of structural birth defects.
The topics listed above are only examples, are not in priority order, and are
not intended to be all-inclusive. Investigators are encouraged to explore and
develop new, innovative projects and research cores that are consistent with
the overall objectives of this PA.
Research Cores
Applicants are encouraged to incorporate the recent scientific advances in
developmental biology and genetics in their projects and to utilize the many
research resources, bioinformatic databases, and biotechnological tools in
their research cores. The research cores should be structured to share work
effort and research resources (e.g., biotechnology, high-throughput
instrumentation, microarrays, oligonucleotide chips, animal model
development, and technical assistance) among the research projects. The aim
of the cores is to enhance the progress, productivity, cost-effectiveness,
and outcome of the research projects.
MECHANISM OF SUPPORT
This PA will use the NIH Program Project Grant (P01) award mechanism. The P01
supports broadly based multidisciplinary research programs that have a well-
defined central research focus or objective. An important feature is that the
interrelationships among the individual projects will result in a greater
contribution to the overall program goals than if each project were pursued
independently. The P01 grant requires a minimum of three interrelated
individual research projects that contribute to the overall program
objective. At least one component project must be translational or clinical
in nature. The application may request support for certain common core
resources. As an applicant you will be solely responsible for planning,
directing, and executing the proposed project.
Guidelines for the NICHD Program Project (P01) Grant may be found at
http://www.nichd.nih.gov/funding/mechanism/p01_guide.cfm.
ELIGIBLE INSTITUTIONS
You may submit an application if your institution has any of the following
characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic institutions/organizations
o Foreign institutions are not eligible to apply
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with his/her institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
SPECIAL REQUIREMENTS
The Program Director for the overall grant and the principal investigator for
each component project should plan to attend an annual NIH-sponsored two-day
meeting in Bethesda, MD. In addition, this meeting will be attended by
investigators supported through the two previous RFAs (HD-99-002, Genetic
Susceptibility & Variability of Human Malformations, and HD-99-008,
Developmental Mechanisms of Human Malformations). The meeting will provide an
opportunity for all the investigators to communicate, discuss the progress of
their research, exchange ideas and information, share resources, and foster
collaborations that are relevant to the research goals of the NICHD birth
defects initiative. This requirement is designed to establish an interactive
network of investigators who are interested in multidisciplinary approaches
to enhancing our understanding of the epidemiology, etiology, pathogenesis,
and developmental biology and genetics of structural birth defects.
All applications should include a request for funds to support attendance of
the Program Director and project principal investigators at the annual
meetings, as well as a statement of agreement to participate in these
meetings and to cooperate with investigators at other program project sites.
A data-sharing plan must be included as outlined in the recent NIH Guide
notice http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PA and welcome the opportunity
answer questions from potential applicants. Inquiries may fall into two
areas: scientific/research and financial or grants management issues:
o Direct your questions about scientific/research issues to:
Lorette Javois, Ph.D.
Developmental Biology, Genetics and Teratology Branch, Center for
Developmental Biology and Perinatal Medicine
National Institute of Child Health and Human Development
6100 Executive Blvd., 4B01 MSC 7510
Bethesda, MD 20892-7510
Telephone: (301) 496-5541
FAX: (301) 480-0303
Email: javoisl@mail.nih.gov
o Direct your questions about financial or grants management matters to:
Annette Hanopole
Grants Management Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard, 8A17, MSC 7510
Bethesda, MD 20892-7510
Telephone: (301) 435-6975
FAX: (301) 402-0915
Email: hanopola@mail.nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the
Universal Identifier when applying for Federal grants or cooperative
agreements. The DUNS number can be obtained by calling (866) 705-5711 or
through the web site at http://www.dunandbradstreet.com/. The DUNS number
should be entered on line 11 of the face page of the PHS 398 form. The PHS 398
is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an
interactive format. For further assistance contact GrantsInfo, Telephone
(301) 710-0267, Email: GrantsInfo@nih.gov.
The title and number of this program announcement must be typed on line 2 of
the face page of the application form and the YES box must be checked.
APPLICATION RECEIPT DATES: Applications submitted in response to this
program announcement will be accepted at the standard application deadlines,
which are available at http://grants.nih.gov/grants/dates.htm. Application
deadlines are also indicated in the PHS 398 application kit.
SPECIFIC INSTRUCTIONS FOR APPLICATIONS REQUESTING $500,000 OR MORE PER YEAR:
Applications requesting $500,000 or more in direct costs for any year must
include a cover letter identifying the NIH staff member within one of NIH
institutes or centers who has agreed to accept assignment of the application.
Applicants requesting more than $500,000 must carry out the following steps:
1) Contact the IC program staff at least six weeks before submitting the
application, i.e., as you are developing plans for the study;
2) Obtain agreement from the IC staff that the IC will accept your
application for consideration for award; and,
3) Identify, in a cover letter sent with the application, the staff member
and IC who agreed to accept assignment of the application.
This policy applies to all investigator-initiated new (type 1), competing
continuation (type 2), competing supplement, or any amended or revised
version of these grant application types. Additional information on this
policy is available in the NIH Guide for Grants and Contracts, October 19,
2001 at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-004.html.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and five signed photocopies in one
package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
APPLICATION PROCESSING: Applications must be mailed on or before the receipt
dates described at
http://grants.nih.gov/grants/funding/submissionschedule.htm.
The CSR will not accept any application in response to this PA that is
essentially the same as one currently pending initial review unless the
applicant withdraws the pending application. The CSR will not accept any
application that is essentially the same as one already reviewed. This does
not preclude the submission of a substantial revision of an application
already reviewed, but such application must include an Introduction
addressing the previous critique.
Although there is no immediate acknowledgement of the receipt of an
application, applicants are generally notified of the review and funding
assignment within eight weeks.
PEER REVIEW PROCESS
Applications submitted for this PA will be assigned on the basis of
established PHS referral guidelines. An appropriate scientific review group
convened in accordance with the standard NIH peer review procedures
(http://www.csr.nih.gov/refrev.htm) will evaluate applications for scientific
and technical merit.
As part of the initial merit review, all applications will:
o Undergo a selection process in which only those applications deemed to have
the highest scientific merit, generally the top half of applications under
review, will be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the appropriate national advisory council
or board.
REVIEW CRITERIA
Applications assigned to NICHD will be evaluated for scientific and technical
merit according to the review criteria outlined in the NICHD Program Project
(P01) Grant Guidelines (http://www.nichd.nih.gov/funding/mechanism/p01_guide.cfm).
ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the following
items will be considered in the determination of scientific merit and the
priority score:
PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human
subjects and protections from research risk relating to their participation
in the proposed research will be assessed. (See criteria included in the
section on Federal Citations, below.)
INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of
plans to include subjects from both genders, all racial and ethnic groups
(and subgroups), and children as appropriate for the scientific goals of the
research will be assessed. Plans for the recruitment and retention of
subjects will also be evaluated. (See Inclusion Criteria in the sections on
Federal Citations, below.)
CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to
be used in the project, the five items described under Section f of the PHS
398 research grant application instructions (rev. 5/2001) will be assessed.
ADDITIONAL REVIEW CONSIDERATIONS
SHARING RESEARCH DATA: Applicants requesting more than $500,000 in direct
costs in any year of the proposed research are expected to include a data
sharing plan in their application. The reasonableness of the data-sharing plan
or the rationale for not sharing research data will be assessed by the
reviewers. However, reviewers will not factor the proposed data sharing plan
into the determination of scientific merit or priority score.
BUDGET: The reasonableness of the proposed budget and the requested period
of support in relation to the proposed research.
AWARD CRITERIA
Applications submitted in response to a PAR will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Relevance to program priorities
REQUIRED FEDERAL CITATIONS
HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that
applications and proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of protection against
these risks, the potential benefits of the research to the subjects and
others, and the importance of the knowledge gained or to be gained
(http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
SHARING RESEARCH DATA: Starting with the October 1, 2003 receipt date,
investigators submitting an NIH application seeking $500,000 or more in direct
costs in any single year are expected to include a plan for data sharing or
state why this is not possible
(http://grants.nih.gov/grants/policy/data_sharing). Investigators should seek
guidance from their institutions, on issues related to institutional policies,
local IRB rules, as well as local, state and Federal laws and regulations,
including the Privacy Rule. Reviewers will consider the data sharing plan but
will not factor the plan into the determination of the scientific merit or the
priority score.
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing clinical research should read the "NIH Guidelines
for Inclusion of Women and Minorities as Subjects in Clinical Research -
Amended, October, 2001," published in the NIH Guide for Grants and Contracts
on October 9, 2001
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines is available at
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable; and
b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported by
the NIH, unless there are scientific and ethical reasons not to include them.
This policy applies to all initial (Type 1) applications submitted for receipt
dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
http://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH
policy requires education on the protection of human subject participants for
all investigators submitting NIH proposals for research involving human
subjects. You will find this policy announcement in the NIH Guide for Grants
and Contracts Announcement, dated June 5, 2000, at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research
on hESCs can be found at http://stemcells.nih.gov/index.asp and at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only
research using hESC lines that are registered in the NIH Human Embryonic Stem
Cell Registry will be eligible for Federal funding (see http://escr.nih.gov).
It is the responsibility of the applicant to provide, in the project
description and elsewhere in the application as appropriate, the official NIH
identifier(s)for the hESC line(s)to be used in the proposed research.
Applications that do not provide this information will be returned without
review.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public archive,
which can provide protections for the data and manage the distribution for an
indefinite period of time. If so, the application should include a
description of the archiving plan in the study design and include information
about this in the budget justification section of the application. In
addition, applicants should think about how to structure informed consent
statements and other human subjects procedures given the potential for wider
use of data collected under this award.
STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The
Department of Health and Human Services (DHHS) issued final modification to
the Standards for Privacy of Individually Identifiable Health Information,
the Privacy Rule, on August 14, 2002. The Privacy Rule is a federal
regulation under the Health Insurance Portability and Accountability Act
(HIPAA) of 1996 that governs the protection of individually identifiable
health information, and is administered and enforced by the DHHS Office for
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified
under the Rule as covered entities ) must do so by April 14, 2003 (with the
exception of small health plans which have an extra year to comply).
Decisions about applicability and implementation of the Privacy Rule reside
with the researcher and his/her institution. The OCR website
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including
a complete Regulation Text and a set of decision tools on Am I a covered
entity? Information on the impact of the HIPAA Privacy Rule on NIH processes
involving the review, funding, and progress monitoring of grants, cooperative
agreements, and research contracts can be found at
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore, we
caution reviewers that their anonymity may be compromised when they directly
access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to
achieving the health promotion and disease prevention objectives of "Healthy
People 2010," a PHS-led national activity for setting priority areas. This PA
is related to one or more of the priority areas. Potential applicants may
obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under the authorization of Sections
301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284)
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All
awards are subject to the terms and conditions, cost principles, and other
considerations described in the NIH Grants Policy Statement. The NIH Grants
Policy Statement can be found at
http://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the
PHS mission to protect and advance the physical and mental health of the
American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|